Trials / Completed
CompletedNCT02649361
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Placebo | Placebo p.o. qd |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-07-23
- Completion
- 2018-07-23
- First posted
- 2016-01-07
- Last updated
- 2019-06-05
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02649361. Inclusion in this directory is not an endorsement.